Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FWD1509 MsOH |
Synonyms | |
Therapy Description |
FWD1509 MsOH is a methanesulfonic acid formulation of the EGFR inhibitor FWD1509, which inhibits mutant forms of EGFR including exon 20 insertions, resulting in decreased downstream signaling and potentially leading to reduced tumor growth (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FWD1509 MsOH | FWD 1509 MsOH|FWD-1509 MsOH | EGFR Inhibitor 4th gen 16 | FWD1509 MsOH is a methanesulfonic acid formulation of the EGFR inhibitor FWD1509, which inhibits mutant forms of EGFR including exon 20 insertions, resulting in decreased downstream signaling and potentially leading to reduced tumor growth (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05068024 | Phase Ib/II | FWD1509 MsOH | A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer (FWD1509) | Recruiting | USA | 0 |